Angel Matthew 4

What Happened

• Angel Matthew, the majority stockholder and Chairman of Factor Biosciences (and reported as a 10% owner), is reporting a purchase: on March 24, 2026 Factor acquired 231,482 shares of Tempest Therapeutics common stock. The reported cash consideration for the shares was $2.16 per combined unit (share + accompanying warrant), totaling $500,001. In addition, Factor received warrants to purchase 462,964 shares (reported as derivative securities).

Key Details

• Transaction date: 2026-03-24. Transaction code: P (purchase).
• Share count purchased: 231,482 common shares for reported cash of $500,001 (effective combined price $2.16 per share + warrant).
• Derivatives: warrants to purchase 462,964 shares were issued to Factor (details subject to stockholder approval per filing).
• Warrant terms noted: Series A warrants become exercisable on the effective date of stockholder approval and run for five years; Series B warrants (also subject to approval) would run for 24 months from approval (per footnotes).
• Reporting relationship: the filing states the Reporting Person (Angel Matthew) is the majority stockholder and Chairman of Factor and exercises voting and investment power over the shares held by Factor.
• Shares owned after transaction: not specified in the provided filing summary.
• Timeliness: filing was reported late due to an inadvertent administrative oversight (the Form 4 indicates a late filing).

Context

• This filing reports a purchase by an affiliated investor entity (Factor) controlled by Angel Matthew, not a stock sale by a company executive. Purchases can be viewed by some investors as a positive/affirmative signal, but filings do not disclose motive. The warrants are derivative instruments and require company stockholder approval before becoming exercisable; the timing and ultimate value will depend on that approval and future stock performance.